Healthcare / BiotechnologyNasdaqGS
$26.92
-0.74 (-2.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-41.2M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$533M
P/E
336.5x
↑EV/EBITDA
N/A
•ROE
-3.0%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-56.9%
FCF / Net income
6.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $72.3M · net income $-6.1M · FCF $-41.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $72.3M | $72.3M | $28.5M | $7.2M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-6.1M | $-6.1M | $-40.2M | $-61.2M | $-93.1M | $-129.9M | $-62.2M | $-97.6M | $-90.8M | $-42.8M | $-44.3M | $-28.5M | $-23.8M | $-19.4M | $-24.8M | $-34.3M | $-15.3M | $-4.5M | $-8.8M | $-4.6M |
| EBITDA | $-12.0M | $-12.0M | $-45.3M | $-64.2M | $-93.6M | $-132.2M | $-64.1M | $-102.2M | $-92.1M | $-52.0M | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.55 | -0.55 | -6.69 | -13.38 | -23.04 | -36.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -16.8% | -16.8% | -159.3% | -902.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -8.5% | -8.5% | -140.9% | -854.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.09 | 0.06 | 0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 6.65 | 6.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $-41.2M | $-41.2M | $-51.1M | $22.5M | $-84.6M | $-96.5M | $-63.4M | $-85.6M | $-65.3M | $995000.00 | $-35.0M | $-18.8M | $-15.1M | $-17.8M | $-21.4M | $-25.1M | $-5.2M | $-3.5M | — | — |
| Returns | ||||||||||||||||||||
| ROE | -3.0% | -3.0% | -120.4% | -149.0% | -112.6% | -76.9% | -25.8% | -35.7% | -43.1% | -37.8% | -55.4% | -24.0% | -40.6% | -79.2% | -139.2% | -99.5% | -131.5% | 34.0% | 92.9% | 104.2% |
| Valuation | ||||||||||||||||||||
| P/E | 336.50 | 336.50 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.46 | 1.46 | 3.15 | 1.08 | 0.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 153.5% | 153.5% | 298.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | 91.8% | 91.8% | 50.0% | 41.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+90.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.69 → -0.55
Residual
+90.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.